Lubner David Charles 4

What Happened
David Charles Lubner, a director of Crescent Biopharma, received a derivative award on 2026-06-02 representing the right to purchase 11,050 ordinary shares. The Form 4 reports the grant at $0.00 per share (derivative), and no immediate cash purchase or sale was reported — this is a compensation grant, not an open-market trade.

Key Details

• Transaction date: 2026-06-02; Form 4 filed: 2026-06-03 (timely filing).
• Award: right to purchase 11,050 shares; reported price on Form 4: $0.00 (derivative).
• Vesting (per footnote): vests in full on the earlier of (i) June 2, 2027 or (ii) the date of the issuer’s next annual meeting, subject to Lubner’s continued service.
• Shares owned after transaction: not specified in the provided excerpt of the filing.
• No 10b5-1 plan, tax-withholding sale, or late-filing flag indicated in the excerpt.

Context
This is a standard equity compensation grant to a director, which is common and typically meant to align interests with shareholders. It should not be read as an open-market purchase or immediate bullish signal; the award vests over time and is contingent on continued service.